VGX-3100
Sponsors
Inovio Pharmaceuticals
Conditions
Anal NeoplasmCervical DysplasiaCervical High Grade Squamous Intraepithelial LesionHSILHuman Papillomavirus (HPV)Papillomavirus InfectionsPre-cancerous Lesions of the VulvaVIN2
Phase 1
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
CompletedNCT00685412
Start: 2008-05-31End: 2011-03-31Updated: 2017-09-13
Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
CompletedNCT01188850
Start: 2010-07-31End: 2011-10-20Updated: 2018-08-10
Phase 2
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
CompletedNCT03180684
Start: 2017-08-31End: 2020-12-18Updated: 2023-08-25
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
CompletedNCT03499795
Start: 2018-05-15End: 2021-05-26Updated: 2023-07-14
Phase 3
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
CompletedNCT03185013
Start: 2017-06-28End: 2021-04-06Updated: 2023-07-27
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
CompletedNCT03721978
Start: 2019-02-28End: 2022-09-15Updated: 2024-10-17